Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:ABP

Abpro 5/15/2025 Earnings Report

Abpro logo
$0.52 0.00 (0.00%)
As of 09/23/2026
ProfileEarnings HistoryForecast

Abpro EPS Results

Actual EPS
-$2.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Abpro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Abpro Announcement Details

Quarter
Date
5/15/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Abpro Earnings Headlines

Abpro Holdings Faces Nasdaq Delisting, Moves to OTC
June 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2334035/abpro-holdings-faces-nasdaq-delisting-moves-to-otc/
Abpro Holdings Directors Resign, Board Seeks Replacements
June 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/31555/abpro-holdings-directors-resign-board-seeks-replacements/
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
 |  Profits Run (Ad)
ABPO Abpro Holdings, Inc.
May 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/ABPO
Abpro Bio Co. Ltd.
April 16, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/195990/financials?countrycode=kr
Abpro Holdings Equity Warrant Exp 12th Nov 2029
April 14, 2026  |  cnbc.comhttps://www.cnbc.com/quotes/ABPWW
See More Abpro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Abpro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abpro and other key companies, straight to your email.

About Abpro

Abpro (NASDAQ:ABP) is a clinical-stage biotechnology company focused on developing antibody-based therapeutics for cancer and other serious diseases. The company uses its proprietary DiversImmune platform to discover and engineer next-generation antibodies, including bispecific antibodies designed to engage the immune system and target disease-associated proteins.

Abpro’s lead product candidate is ABP-100, a bispecific antibody designed to bind HER2 on tumor cells and CD3 on T cells. The company is evaluating ABP-100 as a potential treatment for HER2-expressing cancers. Its broader pipeline includes additional antibody programs at various stages of development.

Abpro operates as a biotechnology company serving the global biopharmaceutical market, with research and development activities focused on advancing its proprietary antibody platform and therapeutic candidates. The company is led by co-founder and Chief Executive Officer Ian Chan and became publicly traded on the Nasdaq under the symbol ABP following a business combination in 2024.

View Abpro Profile
Earnings Tools